ICON’s therapeutic experts regularly contribute to industry publications on medical development challenges. Read more.
Developing drugs for rare diseases involves complexities beyond those typically seen in large trials for more common conditions.
Rapid scientific advancements and emergent therapeutic strategies, including immuno-oncologics and liquid biopsy-based companion diagnostics, are changing oncology research.
ICON's team of therapeutic experts contribute regularly to industry publications in addition to the creation of thought leadership content covering a broad spectrum of therapeutic areas.
Insights on the major trends in aging disorders and pain conditions in clinical trial designs and patient care.
Insights on accelerating study start-up and custom strategies based on lessons learned and best practices.
Cardiovascular disease continues to be leading global cause of death, whilst COVID-19 further raises risk of death for those with underlying cardiovascular conditions.
NASH is a silent disease, massively under-diagnosed due to few, often-mild symptoms and because definitive diagnosis is by histopathology of an invasive liver biopsy.
Insights on clinical programmes involving neonates, children, adolescents, young adults, and pregnant women.
Global studies in endocrine & metabolic disorders is one of our strengths.
Expertise in respiratory clinical trials for drugs, devices, and drug-device combinations.
Specialist expertise and experience to address every stage of your women’s health program.